Apple Machine Learning Algorithms Successfully Detect Colon Cancer but
  Fail to Predict KRAS Mutation Status by Borkowski, Andrew A. et al.
Apple Machine Learning Algorithms Successfully 
Detect Colon Cancer but Fail to Predict KRAS 
Mutation Status 
 
 
Andrew A. Borkowski, MD*1,2, Catherine P. Wilson, MT1, Steven A. Borkowski1, 
L. Brannon Thomas, MD1,2, Lauren A. Deland, RN1,  
Stephen M. Mastorides, MD1,2 
 
 
 
1Pathology and Laboratory Medicine Service, James A. Haley VA Hospital, 
Tampa, Florida, USA. 
 
2Department of Pathology and Cell Biology, University of South Florida, Morsani 
College of Medicine, Tampa, Florida, USA. 
 
 
*aborkows@health.usf.edu 
Pathology and Laboratory Medicine Service (673/113) 
James A Haley VA Hospital 
13000 Bruce B. Downs Blvd 
Tampa, FL 33612 
Tel: 813-972-7525 
 
 
 
 
Keywords: colon cancer, machine learning, create ML, AI, pathology, medicine 
 
  
ABSTRACT 
 
Colon cancer is the second leading cause of cancer-related death in the United States of America. 
Its prognosis has significantly improved with the advancement of targeted therapies based on 
underlying molecular changes. The KRAS mutation is one of the most frequent molecular 
alterations seen in colon cancer and its presence can affect treatment selection. We attempted to 
use Apple machine learning algorithms to diagnose colon cancer and predict the KRAS mutation 
status from histopathological images. We captured 250 colon cancer images and 250 benign 
colon tissue images. Half of colon cancer images were captured from KRAS mutation-positive 
tumors and another half from KRAS mutation-negative tumors. Next, we created Image 
Classifier Model using Apple CreateML machine learning module. The trained and validated 
model was able to successfully differentiate between colon cancer and benign colon tissue 
images with 98 % recall and 98 % precision. However, our model failed to reliably identify 
KRAS mutations, with the highest realized accuracy of 66 %. Although not yet perfected, in the 
near future Apple CreateML modules can be used in diagnostic smartphone-based applications 
and potentially alleviate shortages of medical professionals in understaffed parts of the world.   
  
1. INTRODUCTION 
 
Background and significance 
 
Colon cancer is the second leading cause of cancer-related death in the United States of America. 
According to cancer statistics provided by the American Cancer Society, it is estimated that 
during 2018, 140,250 Americans will be diagnosed with colon cancer and 50,630 will die from 
it.[1] Prognosis in colon cancer has improved with the advancement of targeted therapies based 
on underlying molecular changes.[2] One of the most frequent molecular changes in colon 
cancer is activation of the KRAS proto-oncogene.[3] KRAS mutation status is also the main 
predictive biomarker for treatment selection in colon cancer.[4], [5] 
 
Recent research suggests that using artificial intelligence, one can successfully classify and make 
mutation predictions from non-small cell lung cancer histopathological images. It is reported that 
using deep learning technology, artificial intelligence (AI) is able to predict STK11, EGFR, 
FAT1, SETBP1, KRAS and TP53 gene mutations from pathology images with high accuracy.[6] 
 
Objective  
 
Our objective is to investigate the possibility of using Apple machine learning algorithms to 
diagnose colon cancer and assess the presence of the KRAS mutation from histopathological 
images.  
 
2. MATERIALS AND METHODS 
 
2.1 Image acquisition  
 
Fifty cases of colon adenocarcinoma were retrieved from our molecular database; 25 contained 
KRAS mutations and 25 were negative for KRAS mutations. The 50 cases included 23 biopsies, 
7 polypectomy specimens with invasive adenocarcinoma, and 20 resection specimens. 250 
images of colon cancer (five from each case) were obtained using a Leica Microscope MC190 
HD Camera (Leica Microsystems, Wetzlar, Germany) connected to an Olympus BX41 
microscope (Olympus Corporation of the Americas, Center Valley, PA, USA) and the Leica 
Acquire 9072 software for Apple computers. All the images were captured at a resolution of 
1024 x 768 pixels using a 60x dry objective and saved on a 2011 Apple iMac computer (Apple 
Inc, Cupertino, CA, USA) running macOS v10.13.6. In addition, 250 images of benign colonic 
mucosa were obtained from negative distal margin sections of resection specimens. 
 
2.2 Xcode Image Classifier builder in Playground 
 
As we described previously we used the Apple Xcode Playground v10 on a 2018 Apple 
MacBook Pro running macOS v10.14 to create ImageClassifier Model with following lines of 
code. [7]  
 
import CreateMLUI 
let builder = MLImageClassifierBuilder() 
builder.showInLiveView() 
 
We opened the assistant editor in Xcode and then ran the code. The live view displayed the 
image classifier UI.  We then dragged the training folder for training the model and the testing 
folder to evaluate the model on the indicated locations in live view.  
 
2.3 Experiment 1 
 
In this experiment, we tested the Apple Create ML model to detect colon cancer 
histopathological images regardless of KRAS mutation status. We created two classes of images 
(250 images each) with the following labels: Benign (benign colon tissue) and AdenoCA (colon 
adenocarcinoma). 80% of the images were randomly assigned to the training folder and 20% to 
the testing folder. The training folder included two class labeled subfolders with training images 
(80% of total).  The testing folder included two class labeled subfolders with testing images 
(20% of total). In our previous work, we found that the best results are obtained with 50 
iterations and no additional augmentation of images. 
 
 We then trained and tested our model with 50 iterations, 10 times (Table 1). 
 
2.4 Experiment 2 
 
In this experiment, we tested the Apple Create ML model to differentiate between KRAS 
mutation-positive colon adenocarcinoma and KRAS mutation-negative colon adenocarcinoma 
histopathologic images. We created two classes of images (125 images each) with the following 
labels: KRAS+ (colon adenocarcinoma cases with KRAS mutation) and KRAS- (colon 
adenocarcinoma cases without KRAS mutation). The training folder included two class labeled 
subfolders with training images (80% of total). The testing subfolder included two class labeled 
subfolders with testing images (20% of total). We tested our model with 50 iterations, 10 times 
(Table 2). 
 
Next, we tested the same image data sets with various image augmentations (crop, rotate, blur, 
expose, noise, flip, a combination of rotate and flip, a combination of rotate and noise) (Table 3). 
 
3. RESULTS 
 
When testing benign colon tissue images against colon adenocarcinoma images our model was 
able to differentiate between the two with 98% recall and 98% precision. In other words, our AI 
model could correctly differentiate benign colon tissue and malignant colon tissue 98% of the 
time. 
 
When testing KRAS+ colon adenocarcinoma images against KRAS- colon adenocarcinoma 
images our model failed to adequately differentiate between the two. Although training accuracy 
was 100%, validation accuracy was 63% and testing accuracy was only 50% (same accuracy as 
flipping the coin). 
 
Next, we tried to improve our model by adding various image augmentations. The best results 
were obtained with a rotation of images with testing accuracy increasing to 66%. 
 
 
4. DISCUSSION 
 
In this study, we designed several experiments to test the ability of an Apple Create ML model to 
distinguish the difference between KRAS mutation-positive colon adenocarcinomas and KRAS 
mutation-negative colon adenocarcinomas. The model accurately classified and distinguished 
between colon cancer versus benign colon images 98% of the time; however, the model had far 
less success distinguishing between a KRAS positive mutation image and KRAS negative 
mutation image.  
 
The discovery of target therapies in cancer treatments, due to underlining molecular mechanisms, 
has led to a revolutionary wave of testing involving the identification of molecular mutations. [3] 
The identification of the KRAS mutation in colon adenocarcinoma indicates a major directional 
change in the patient’s oncological treatment options. [2] Classification of molecular mutations 
such as KRAS is essential to the future of healthcare and cancer treatment directions.[4] 
 
In the initial stages of AI program development, most applications were written and tested for 
large data groups. Programs were utilized in cloud environments with extremely large numbers 
of data sets.[8] Deep learning techniques were applied to many areas of medical research such as 
dermatology, pathology, and radiology.[9]–[15] Recent smaller scale incorporations of AI 
programs have shown even more promising results.[16]  Smaller scale applications have been 
created for smartphones highlighting AI’s potential for universal accessibility and ease of 
use.[17][18] Visual DX and other smartphone applications allow for a widespread image 
analysis with low cost and the ability to triage cases for further indicated medical treatments.[19] 
The widespread availability of handheld applications would alleviate some of the strain caused 
by global pathologist shortages.[20]  
 
Recent studies with medical AI programs have demonstrated several advantages. AI programs 
have a potential for faster test completion and reported results, versus timing and labor 
involvement in other medical procedures.[21] Image analysis programs created for pathology 
may be able to conserve the amounts of tissue required to diagnose cancer from minimal tumor 
microenvironments.[21] Successful detection of underlying molecular mutations by use of AI 
image analysis may function to triage positive cancer images, lowering the cost of highly 
complex, time-consuming DNA detection assays.[6], [9] 
 
 
5. CONCLUSIONS 
 
Our model was able to successfully diagnose cancer but was unreliable in the detection of 
pathomorphological expressions of the KRAS mutation. Experiments with increased numbers of 
histopathological images may be able to distinguish underlying KRAS molecular mutations. 
Additional future experiments may include comparisons of the Apple CreateML model with 
Google cloud machine learning Cloud AutoML to see if timing or accuracy can be 
improved.[22], [23] 
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TABLES 
 
 
Accuracy (%)       Recall  (%) Precision (%) 
Run Training Validation Testing Benign ColonCA Benign ColonCA 
1 100 100 98 98 98 98 98 
2 100 100 98 98 98 98 98 
3 100 100 98 98 98 98 98 
4 100 100 99 98 100 100 98 
5 100 100 98 98 98 98 98 
6 100 100 98 98 98 98 98 
7 100 100 98 98 98 98 98 
8 100 100 98 98 98 98 98 
9 100 100 98 98 98 98 98 
10 100 100 98 98 98 98 98 
Median 100 100 98 98 98 98 98 
Average 100 100 98 98 98.2 98.2 98 
        
Table 1. Training, validation, and testing. Colon cancer versus benign colon tissue images. 
 
 
 
Accuracy %        Recall (%) Precision % 
Run Training Validation Testing 
ColonCA 
(KRAS+) 
ColonCA 
(KRAS-) 
ColonCA 
(KRAS+) 
ColonCA 
(KRAS-) 
1 100 63 50           44 56 50 50 
2 100 63 50 44 56 50 50 
3 100 63 50 44 56 50 50 
4 100 63 50 44 56 50 50 
5 100 50 48 40 56 48 48 
6 100 63 50 44 56 50 50 
7 100 50 48 40 56 48 48 
8 100 63 50 44 56 50 50 
9 100 50 48 40 56 48 48 
10 100 63 50 44 56 50 50 
Median 100 63 50 44 56 50 50 
Average 100 59.1 49.4 42.667 56 49.4 49.4 
 
Table 2. Training, validation, and testing. KRAS positive versus KRAS negative colon cancer 
images. 
  
Augmentation Accuracy %    Recall (%) Precision % 
  Training Validation Testing 
ColonCA 
(KRAS+) 
ColonCA 
(KRAS-) 
ColonCA 
(KRAS+) 
ColonCA 
(KRAS-) 
Crop 100 50 52 40 64 53 52 
Rotate 100 63 66 60 72 68 64 
Blur 100 63 52 48 56 52 52 
Expose 100 63 44 48 40 44 43 
Noise 100 63 54 44 64 55 53 
Flip 100 50 56 60 52 56 57 
Rotate + Flip 100 63 50 60 40 50 50 
Rotate + Noise 100 50 52 40 64 53 52 
 
Table 3. Training, validation, and testing. KRAS positive versus KRAS negative colon cancer 
images with different image augmentations. 
